Tonix Historical Balance Sheet

TNXP Stock

USD 0.19 0.01 5.00%

Trend analysis of Tonix Pharmaceuticals Holding balance sheet accounts such as Cash of 37.7 M, Cash And Short Term Investments of 39.9 M, Net Receivables of 3.8 M or Common Stock Total Equity of 598.9 K provides information on Tonix Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Tonix Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Tonix Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Tonix Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tonix Pharmaceuticals is a good buy for the upcoming year.

Tonix Pharmaceuticals Inventory

14.85 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Tonix Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Tonix Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Tonix Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Tonix Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Tonix currently owns. An asset can also be divided into two categories, current and non-current.

Tonix Pharmaceuticals Balance Sheet Chart

At this time, Tonix Pharmaceuticals' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/24/2024, Other Stockholder Equity is likely to grow to about 741.7 M, though Retained Earnings are likely to grow to (570.6 M).

Total Assets Other Current Liab Total Current Liabilities Cash And Short Term Investments Net Invested Capital

Add Fundamental

Total Assets

Total assets refers to the total amount of Tonix Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tonix Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Tonix Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Tonix Pharmaceuticals Holding are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Tonix Pharmaceuticals balance sheet. This account contains Tonix Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Tonix Pharmaceuticals Holding fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most accounts from Tonix Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Tonix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	5.1M	6.4M	9.5M	10.0M
Total Assets	240.9M	225.7M	154.5M	162.2M

Other Current Liab Total Assets

Tonix Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Short Long Term Debt Total	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt
Total Assets		0.83	0.96	0.94	-0.8	-0.84	0.86	0.85	0.83	0.92	0.59	0.23	0.92	0.73	0.89	0.69	0.88	0.42	0.89	0.94	0.86	0.69	0.84	0.11	0.57	0.68
Other Current Liab	0.83		0.92	0.62	-0.34	-0.94	0.44	0.43	0.64	0.96	0.93	0.14	0.94	0.97	0.5	0.33	0.51	0.82	0.89	0.96	0.97	0.61	0.98	0.07	0.2	0.69
Total Current Liabilities	0.96	0.92		0.85	-0.66	-0.91	0.73	0.73	0.8	0.97	0.73	0.27	0.96	0.86	0.78	0.63	0.81	0.59	0.93	0.98	0.91	0.68	0.9	0.15	0.5	0.74
Total Stockholder Equity	0.94	0.62	0.85		-0.92	-0.68	0.94	0.94	0.85	0.77	0.33	0.25	0.77	0.49	0.96	0.75	0.94	0.14	0.76	0.8	0.69	0.7	0.65	0.08	0.64	0.56
Net Debt	-0.8	-0.34	-0.66	-0.92		0.42	-0.99	-0.99	-0.74	-0.54	0.0	-0.17	-0.55	-0.2	-0.98	-0.86	-0.94	0.16	-0.57	-0.57	-0.4	-0.55	-0.36	0.01	-0.78	-0.42
Retained Earnings	-0.84	-0.94	-0.91	-0.68	0.42		-0.5	-0.49	-0.61	-0.92	-0.85	-0.27	-0.99	-0.91	-0.56	-0.36	-0.58	-0.72	-0.92	-0.94	-0.92	-0.51	-0.93	-0.22	-0.21	-0.82
Cash	0.86	0.44	0.73	0.94	-0.99	-0.5		0.99	0.77	0.62	0.11	0.17	0.63	0.31	0.99	0.87	0.96	-0.05	0.65	0.65	0.49	0.58	0.45	0.01	0.78	0.48
Cash And Short Term Investments	0.85	0.43	0.73	0.94	-0.99	-0.49	0.99		0.76	0.61	0.1	0.27	0.62	0.3	0.99	0.86	0.96	-0.07	0.63	0.65	0.47	0.59	0.43	0.02	0.78	0.45
Net Receivables	0.83	0.64	0.8	0.85	-0.74	-0.61	0.77	0.76		0.76	0.39	0.13	0.69	0.53	0.81	0.69	0.79	0.26	0.8	0.74	0.65	0.82	0.63	0.05	0.45	0.54
Common Stock Total Equity	0.92	0.96	0.97	0.77	-0.54	-0.92	0.62	0.61	0.76		0.83	0.11	0.95	0.91	0.66	0.53	0.69	0.71	0.94	0.99	0.97	0.63	0.96	0.18	0.39	0.73
Common Stock Shares Outstanding	0.59	0.93	0.73	0.33	0.0	-0.85	0.11	0.1	0.39	0.83		0.06	0.81	0.97	0.17	0.06	0.21	0.95	0.75	0.82	0.89	0.39	0.91	0.13	-0.04	0.6
Short Term Investments	0.23	0.14	0.27	0.25	-0.17	-0.27	0.17	0.27	0.13	0.11	0.06		0.26	0.15	0.29	0.09	0.28	-0.02	0.15	0.2	0.1	0.22	0.1	0.26	0.07	0.11
Other Stockholder Equity	0.92	0.94	0.96	0.77	-0.55	-0.99	0.63	0.62	0.69	0.95	0.81	0.26		0.89	0.67	0.46	0.68	0.65	0.95	0.97	0.94	0.57	0.93	0.19	0.32	0.8
Total Liab	0.73	0.97	0.86	0.49	-0.2	-0.91	0.31	0.3	0.53	0.91	0.97	0.15	0.89		0.37	0.29	0.41	0.91	0.85	0.91	0.91	0.49	0.93	0.14	0.18	0.68
Total Current Assets	0.89	0.5	0.78	0.96	-0.98	-0.56	0.99	0.99	0.81	0.66	0.17	0.29	0.67	0.37		0.86	0.97	0.0	0.68	0.7	0.53	0.63	0.49	0.04	0.76	0.5
Common Stock	0.69	0.33	0.63	0.75	-0.86	-0.36	0.87	0.86	0.69	0.53	0.06	0.09	0.46	0.29	0.86		0.88	0.02	0.57	0.54	0.31	0.45	0.29	0.13	0.92	0.43
Accounts Payable	0.88	0.51	0.81	0.94	-0.94	-0.58	0.96	0.96	0.79	0.69	0.21	0.28	0.68	0.41	0.97	0.88		0.05	0.69	0.71	0.55	0.61	0.52	0.13	0.81	0.56
Short Long Term Debt Total	0.42	0.82	0.59	0.14	0.16	-0.72	-0.05	-0.07	0.26	0.71	0.95	-0.02	0.65	0.91	0.0	0.02	0.05		0.64	0.69	0.75	0.2	0.78	0.14	-0.08	0.53
Other Liab	0.89	0.89	0.93	0.76	-0.57	-0.92	0.65	0.63	0.8	0.94	0.75	0.15	0.95	0.85	0.68	0.57	0.69	0.64		0.93	0.87	0.58	0.87	0.21	0.35	0.86
Net Tangible Assets	0.94	0.96	0.98	0.8	-0.57	-0.94	0.65	0.65	0.74	0.99	0.82	0.2	0.97	0.91	0.7	0.54	0.71	0.69	0.93		0.96	0.64	0.95	0.12	0.41	0.72
Property Plant And Equipment Net	0.86	0.97	0.91	0.69	-0.4	-0.92	0.49	0.47	0.65	0.97	0.89	0.1	0.94	0.91	0.53	0.31	0.55	0.75	0.87	0.96		0.58	1.0	0.16	0.2	0.69
Current Deferred Revenue	0.69	0.61	0.68	0.7	-0.55	-0.51	0.58	0.59	0.82	0.63	0.39	0.22	0.57	0.49	0.63	0.45	0.61	0.2	0.58	0.64	0.58		0.57	-0.16	0.31	0.27
Non Current Assets Total	0.84	0.98	0.9	0.65	-0.36	-0.93	0.45	0.43	0.63	0.96	0.91	0.1	0.93	0.93	0.49	0.29	0.52	0.78	0.87	0.95	1.0	0.57		0.16	0.18	0.69
Non Currrent Assets Other	0.11	0.07	0.15	0.08	0.01	-0.22	0.01	0.02	0.05	0.18	0.13	0.26	0.19	0.14	0.04	0.13	0.13	0.14	0.21	0.12	0.16	-0.16	0.16		0.07	0.28
Other Assets	0.57	0.2	0.5	0.64	-0.78	-0.21	0.78	0.78	0.45	0.39	-0.04	0.07	0.32	0.18	0.76	0.92	0.81	-0.08	0.35	0.41	0.2	0.31	0.18	0.07		0.26
Long Term Debt	0.68	0.69	0.74	0.56	-0.42	-0.82	0.48	0.45	0.54	0.73	0.6	0.11	0.8	0.68	0.5	0.43	0.56	0.53	0.86	0.72	0.69	0.27	0.69	0.28	0.26

Click cells to compare fundamentals

Tonix Pharmaceuticals Account Relationship Matchups

Tonix Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.6M	98.2M	240.9M	225.7M	154.5M	162.2M
Other Current Liab	1.0M	2.5M	5.1M	6.4M	9.5M	10.0M
Total Current Liabilities	5.1M	9.8M	21.7M	18.2M	18.9M	19.8M
Total Stockholder Equity	9.4M	87.6M	218.7M	207.2M	105.5M	53.9M
Net Debt	(10.9M)	(75.8M)	(177.7M)	(119.5M)	(15.1M)	(15.9M)
Retained Earnings	(217.1M)	(267.5M)	(359.8M)	(470.0M)	(600.7M)	(570.6M)
Cash	11.2M	77.1M	178.7M	120.2M	24.9M	37.7M
Cash And Short Term Investments	11.2M	77.1M	178.7M	120.2M	24.9M	39.9M
Net Receivables	1.0M	7.6M	7.7M	8.0M	6.1M	3.8M
Common Stock Total Equity	3K	9K	206K	496K	570.4K	598.9K
Common Stock Shares Outstanding	8.0K	14.8K	56.9K	182.5K	532.5K	559.1K
Liabilities And Stockholders Equity	14.6M	98.2M	240.9M	225.7M	154.5M	162.2M
Other Stockholder Equity	226.5M	355.0M	578.6M	677.3M	706.4M	741.7M
Total Liab	5.1M	10.5M	22.2M	18.5M	48.9M	51.4M
Total Current Assets	13.9M	88.0M	189.0M	130.8M	47.8M	44.4M
Common Stock	9K	206K	496K	76K	59K	67.6K
Accounts Payable	3.1M	4.6M	13.3M	8.1M	3.8M	3.2M
Net Tangible Assets	9.3M	87.5M	218.7M	207.2M	238.3M	250.2M
Property Plant And Equipment Net	390K	9.8M	51.5M	94.5M	94.9M	99.6M
Current Deferred Revenue	704K	2.2M	2.8M	3.3M	3.0M	1.7M
Non Current Assets Total	610K	10.2M	51.9M	94.9M	106.7M	112.0M
Retained Earnings Total Equity	(188.5M)	(217.1M)	(267.5M)	(359.8M)	(323.8M)	(307.6M)
Non Current Liabilities Total	6K	716K	467K	328K	30.0M	31.6M
Capital Surpluse	212.2M	226.5M	355.0M	578.1M	664.9M	698.1M
Other Current Assets	2.7M	3.3M	2.7M	10.5M	2.6M	2.2M
Property Plant And Equipment Gross	390K	9.8M	51.9M	96.2M	100.2M	105.2M
Accumulated Other Comprehensive Income	(46K)	(62K)	(92K)	(167K)	(232K)	(220.4K)
Property Plant Equipment	34K	9.8M	51.5M	94.5M	108.7M	114.1M
Net Invested Capital	9.4M	87.6M	218.7M	207.2M	112.1M	107.4M
Net Working Capital	8.8M	78.2M	167.3M	112.6M	28.9M	27.4M
Capital Stock	9K	206K	496K	76K	59K	56.1K

Pair Trading with Tonix Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tonix Stock

0.61

VALN

Valneva SE ADR

Pair Corr

Moving against Tonix Stock

0.63

NXGLW

NexGel Warrant

Pair Corr

The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.

The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Tonix Stock Analysis

When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tonix Historical Balance Sheet

Tonix Pharmaceuticals Inventory

14.85 Million

About Tonix Balance Sheet Analysis

Tonix Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Cash And Short Term Investments

Net Invested Capital

Tonix Pharmaceuticals balance sheet Correlations

Tonix Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tonix Pharmaceuticals balance sheet Accounts

Pair Trading with Tonix Pharmaceuticals

Moving together with Tonix Stock

Moving against Tonix Stock

Additional Tools for Tonix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Net Tangible Assets	+ 0.99	Common Stock Total Equity
Non Current Assets Total	+ 0.98	Other Current Liab

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Tangible Assets	- 0.94	Retained Earnings
Accounts Payable	- 0.94	Net Debt